Patents by Inventor Christoph Petry
Christoph Petry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913078Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: October 27, 2020Date of Patent: February 27, 2024Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Torne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20220307090Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.Type: ApplicationFiled: April 6, 2022Publication date: September 29, 2022Applicant: Myriad International GmbHInventors: Mathias Gehrmann, Karsten Weber, Ralf Kronenwett, Christoph Petry, Jan Brase
-
Publication number: 20210268748Abstract: The invention relates to a method for increasing the dosing precision of microfluidic pumps and valves based on a flexible cover film/diaphragm and a valve trough, in which the surface of the diaphragm facing the valve trough is heated with a laser beam.Type: ApplicationFiled: November 29, 2019Publication date: September 2, 2021Applicant: m2p-labs GmbHInventors: Niklas FRISCHE, Alexander KREMERS, Karlheinz HILDENBRAND, Christoph PETRY
-
Publication number: 20210123107Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: October 27, 2020Publication date: April 29, 2021Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TORNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10851427Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: January 17, 2020Date of Patent: December 1, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20200224281Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: January 17, 2020Publication date: July 16, 2020Applicant: MYRIAD INTERNATIONAL GMBHInventors: Mareike DARTMANN, Inke Sabine FEDER, Mathias GEHRMANN, Guido HENNIG, Karsten WEBER, Christian VON TÖRNE, Ralf KRONENWETT, Christoph PETRY
-
Patent number: 10577661Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: GrantFiled: August 11, 2016Date of Patent: March 3, 2020Assignee: MYRIAD INTERNATIONAL GMBHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20190144949Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.Type: ApplicationFiled: January 24, 2019Publication date: May 16, 2019Inventors: Mathias Gehrmann, Karsten Weber, Ralf Kronenwett, Christoph Petry, Jan Brase
-
Publication number: 20190010558Abstract: Provided herein are methods for predicting a result relating to breast cancer in a patient, the method comprising (a) determining the RNA expression levels of three or more of the following 8 genes in a tumor sample from the patient: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST and MGP; and (b) mathematically combining the expression level values for the genes of the mentioned set to obtain a combined score, the combined score indicating a prognosis for the patient, wherein the RNA expression level values have at least in part not been normalized before the mathematical combination.Type: ApplicationFiled: September 7, 2018Publication date: January 10, 2019Inventors: Karsten Weber, Marsel Scheer, Christoph Petry
-
Publication number: 20170081728Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.Type: ApplicationFiled: September 23, 2016Publication date: March 23, 2017Applicant: Sividon Diagnostics GMBHInventors: Mathias Gehrmann, Karsten Weber, Ralf Kronenwett, Christoph Petry, Jan Christoph Brase
-
Publication number: 20170067118Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: August 11, 2016Publication date: March 9, 2017Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20140228241Abstract: A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.Type: ApplicationFiled: July 30, 2012Publication date: August 14, 2014Applicant: Sividon Diagnostics GmbHInventors: Mathias Gehrmann, Karsten Weber, Ralf Kronenwett, Christoph Petry, Jan Christoph Brase
-
Publication number: 20130183710Abstract: The present invention relates to a reference sample for quality control purposes in molecular diagnosis of biological samples, which reference sample comprises a mixture of cells from at least one reference cell line which exhibits a particular gene expression profile, and at least one type of lymphocytes. Furthermore, the invention relates to productions methods for such references samples as well as to methods of their use.Type: ApplicationFiled: July 18, 2011Publication date: July 18, 2013Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Elke Reifenberger, Petra Walter, Christoph Petry
-
Publication number: 20130065786Abstract: The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.Type: ApplicationFiled: March 29, 2011Publication date: March 14, 2013Applicant: Sividon Diagnostics GmbHInventors: Mareike Dartmann, Inke Sabine Feder, Mathias Gehrmann, Guido Hennig, Karsten Weber, Christian Von Törne, Ralf Kronenwett, Christoph Petry
-
Publication number: 20110046455Abstract: A tip of an elongate device is navigated into a particular tissue volume in order to examine the particular tissue volume in a body and part of the tissue volume is analyzed in real-time by way of a biosensor. In at least one embodiment, in the process, either the biosensor can be arranged on the tip of the device or the device includes a catheter, by which a substance to be analyzed is transported out of the tissue volume from the tip to the biosensor arranged at the proximal end of the catheter.Type: ApplicationFiled: August 17, 2010Publication date: February 24, 2011Inventors: Arne HENGERER, Andreas Kappel, Luis Lasalvia, Andrea Lichte, Thomas Mertelmeier, Sven Meyburg, Christoph Petry, Marcus Pfister, Martin Requardt
-
Publication number: 20100247438Abstract: An in vitro method is for diagnosing a tumor disease in a patient.Type: ApplicationFiled: March 25, 2010Publication date: September 30, 2010Inventors: Arne Hengerer, Andreas Kappel, Luis Lasalvia, Andrea Lichte, Thomas Mertelmeier, Sven Meyburg, Christoph Petry, Marcus Pfister, Martin Requardt
-
Publication number: 20100240970Abstract: An embodiment of the present invention relates to a device, which can be implanted into a patient, for an in vivo measurement. In an embodiment, the device includes a catheter for guiding a sample of the patient town analysis unit in the device. A measurement result is determined in the analysis unit by analyzing the sample with the aid of a reagent. In an embodiment, the device furthermore includes an interchange chamber, with the aid of which the reagent can be removed from the device or can be inserted into the device. The interchange chamber has a connector allowing removal or insertion of the reagent while the device is implanted.Type: ApplicationFiled: March 15, 2010Publication date: September 23, 2010Inventors: Arne HENGERER, Andreas Kappel, Luis Lasalvia, Andrea Lichte, Thomas Mertelmeier, Sven Meyburg, Christoph Petry, Marcus Pfister, Martin Requardt
-
Patent number: 7668661Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.Type: GrantFiled: June 15, 2004Date of Patent: February 23, 2010Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Michael Volker, Michael Becka, Werner Kroll, Andreas Knorr, Sylvia Unger, Mathias Gehrmann, Guido Hennig, Elmar-Reinhold Burchardt, Michael J. Arthur, Alastair D. Burt, Massimo Pinzani, Detlef Schuppan, Robert P. Thiel, Christoph Petry, William Rosenberg
-
Publication number: 20080233582Abstract: The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods.Type: ApplicationFiled: January 25, 2008Publication date: September 25, 2008Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Monika Stoll, Gerd Assmann, Helmut Schulte, Werner Kroll, Stephan Schwers, Christoph Petry
-
Publication number: 20070172907Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.Type: ApplicationFiled: June 15, 2004Publication date: July 26, 2007Inventors: Michael Volker, Michael Becka, Werner Kroll, Andreas Knorr, Sylvia Unger, Mathias Gehrmann, Guido Hennig, Elmar-Reinhold Burchardt, Michael Arthur, Alastair Burt, Massimo Pinzani, Detlef Schuppan, Robert Thiel, Christoph Petry, William Rosenberg